Study Protocol for Evaluation of Calcium Dobesilate Efficacy on SARS-CoV-2 Viral Load in COVID-19 Outpatients
Key Highlights
The CADOVID trial aims to assess the effectiveness and safety of Calcium Dobesilate (CaD) in reducing SARS-CoV-2 viral load and mitigating persistent COVID-19 symptoms in non-hospitalized adult patients diagnosed with COVID-19.
The trial is a randomized, placebo-controlled, double-blind, monocentric phase II study, with 74 adult patients randomly assigned to receive either CaD or a placebo.
Participants in the CaD group will take two 500 mg capsules of CaD twice daily for 7 days, followed by a 77-day observation period, while the placebo group will receive matching capsules of mannitol.
Online questionnaires and SARS-CoV-2 PCR testing will be used to assess symptoms, temperature, and viral load reduction over the course of the trial.
Ethical Approval and Dissemination
The trial has received approval from the Geneva Regional Research Ethics Committee and Swissmedic. Results will be shared through scientific conferences and publication in scientific journals.
Registration Information
Trial registration number: NCT05305508; Clinicaltrials.gov; Swiss National Clinical Portal Registry (SNCTP 000004938).
Practical Solutions and Value
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates standards, protocols, and research for easy access by clinicians, helping to extend the benefits of clinical trials into everyday medical practice.
Streamlining operations is crucial in today’s healthcare environment. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
By utilizing AI, clinics can improve workflows, enhance patient outcomes, and reduce paper-based routines. Learn more about how we can help at aidevmd.com.
